Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2012 Mar;47(3):284-92.
doi: 10.1007/s00535-011-0488-5. Epub 2011 Nov 15.

Rikkunshito improves symptoms in PPI-refractory GERD patients: a prospective, randomized, multicenter trial in Japan

Kazunari Tominaga  1 , Ryuichi Iwakiri, Kazuma Fujimoto, Yasuhiro Fujiwara, Mio Tanaka, Yasuyuki Shimoyama, Eiji Umegaki, Kazuhide Higuchi, Motoyasu Kusano, Tetsuo Arakawa; GERD 4 Study Group
Affiliations
Randomized Controlled Trial

Rikkunshito improves symptoms in PPI-refractory GERD patients: a prospective, randomized, multicenter trial in Japan

Kazunari Tominaga et al. J Gastroenterol. 2012 Mar.

Abstract

Background: To seek a promising therapeutic regimen for proton pump inhibitor (PPI)-refractory patients with gastroesophageal reflux disease (GERD) after the standard PPI treatment, we compared the efficacies of rikkunshito (a Japanese traditional medication) combined with rabeprazole (RPZ) and a double dose of RPZ in a prospective randomized multicenter trial in Japanese PPI-refractory GERD patients.

Methods: One hundred and four patients with GERD symptoms remaining after 4-week treatment with RPZ (10 mg/day) were randomly assigned to 4 weeks of either combination therapy [rikkunshito (7.5 g/day) with a standard dose of RPZ (10 mg/day)] or a double dose of RPZ (20 mg/day). The primary endpoint was the improvement rate, calculated based on the frequency scale for the symptoms of GERD (FSSG) before and after treatment. Subgroup analysis was also performed with respect to each subject's background factors such as reflux esophagitis (RE)/non-erosive GERD (NERD), age, gender, and body mass index (BMI).

Results: Four-week treatment with rikkunshito combined with RPZ significantly decreased the FSSG score from 17.6 ± 6.5 to 12.0 ± 6.9, similar to the decrease seen on treatment with a double dose of RPZ. Regarding the therapeutic improvement rate, there were also significant effects in both groups. However, in the subgroup analysis based on RE/NERD, the improvement rate of male NERD patients in the rikkunshito group was significantly greater than that of such patients in the other group (P < 0.05). In the rikkunshito group, the treatment was more effective in NERD patients with a low BMI than in those with a high BMI (P < 0.05).

Conclusion: Rikkunshito combined with standard-dose RPZ therapy may be a useful new strategy for PPI-refractory GERD patients.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Pediatr Surg Int. 2007 Oct;23(10):1001-5 - PubMed
    1. Endocrinology. 2010 Aug;151(8):3773-82 - PubMed
    1. J Gastroenterol. 2010 Apr;45(4):413-21 - PubMed
    1. J Gastroenterol. 2009;44(3):183-9 - PubMed
    1. World J Gastroenterol. 2005 Jul 21;11(27):4210-4 - PubMed

Publication types

MeSH terms

LinkOut - more resources